Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
2013; Elsevier BV; Volume: 122; Issue: 10 Linguagem: Inglês
10.1182/blood-2013-06-506725
ISSN1528-0020
AutoresRoland B. Walter, Sarah Buckley, John M. Pagel, Brent L. Wood, Barry E. Storer, Brenda M. Sandmaier, Min Fang, Boglarka Gyurkocza, Colleen Delaney, Jerald P. Radich, Elihu H. Estey, Frederick R. Appelbaum,
Tópico(s)Retinoids in leukemia and cellular processes
ResumoKey Points The negative impact of pre-HCT flow cytometrically determined MRD is similar for AML in CR1 and CR2. Even minute levels of MRD (≤0.1%) are associated with adverse outcome.
Referência(s)